CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML) - CHARM Therapeutics

Menin inhibitors have emerged as a clinically validated therapeutic class for the treatment of acute AML. However, first-generation inhibitors are limited by the rapid emergence of resistance mutations in menin that reduce efficacy and lead to disease progression.